|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Systematic review and meta-analysis This trial is included in the following systematic reviews and meta-analyses:
Related trials
See also: |
Treatments
Patients
Method and design
Results
|
Endpoint | Events (%) | Relative Risk | 95% CI | ||
---|---|---|---|---|---|
Studied treat. | Control treat. | ||||
CHD death, stroke, MI, above ankle amputation | 117 / 640 (18,3%) | 116 / 636 (18,2%) | 1,00 | [0,79;1,26] | |
Death from coronary heart disease or stroke | 42 / 640 (6,6%) | 36 / 636 (5,7%) | 1,16 | [0,75;1,78] | |
Death (any cause) | 115 / 640 (18,0%) | 80 / 636 (12,6%) | 1,43 | [1,10;1,86] | |
Coronary heart disease death | 30 / 640 (4,7%) | 31 / 636 (4,9%) | 0,96 | [0,59;1,57] | |
Stroke death | 12 / 640 (1,9%) | 5 / 636 (0,8%) | 2,39 | [0,85;6,73] | |
Non-fatal myocardial infarction | 49 / 640 (7,7%) | 62 / 636 (9,7%) | 0,79 | [0,55;1,12] | |
Non-fatal stroke | 36 / 640 (5,6%) | 34 / 636 (5,3%) | 1,05 | [0,67;1,66] | |
Above ankle amputation for critical limb ischaemia | 10 / 640 (1,6%) | 10 / 636 (1,6%) | 0,99 | [0,42;2,37] | |
Transient ischaemic attack | 11 / 640 (1,7%) | 23 / 636 (3,6%) | 0,48 | [0,23;0,97] | |
Coronary artery bypass surgery | 12 / 640 (1,9%) | 14 / 636 (2,2%) | 0,85 | [0,40;1,83] | |
Coronary artery angioplasty | 7 / 640 (1,1%) | 8 / 636 (1,3%) | 0,87 | [0,32;2,38] | |
Development of angina | 69 / 640 (10,8%) | 79 / 636 (12,4%) | 0,87 | [0,64;1,18] | |
Peripheral arterial bypass surgery | 4 / 640 (0,6%) | 8 / 636 (1,3%) | 0,50 | [0,15;1,64] | |
Peripheral arterial angioplasty | 12 / 640 (1,9%) | 12 / 636 (1,9%) | 0,99 | [0,45;2,20] | |
Development of critical limb ischaemia | 22 / 640 (3,4%) | 18 / 636 (2,8%) | 1,21 | [0,66;2,24] | |
Development of claudication | 97 / 640 (15,2%) | 107 / 636 (16,8%) | 0,90 | [0,70;1,16] | |
Malignancy | 65 / 640 (10,2%) | 56 / 636 (8,8%) | 1,15 | [0,82;1,62] | |
Gastrointestinal bleeding | 28 / 640 (4,4%) | 31 / 636 (4,9%) | 0,90 | [0,54;1,48] | |
Gastrointestinal symptoms, including dyspepsia | 69 / 640 (10,8%) | 98 / 636 (15,4%) | 0,70 | [0,52;0,93] | |
Arrhythmia | 50 / 640 (7,8%) | 52 / 636 (8,2%) | 0,96 | [0,66;1,39] | |
Allergy including skin rash | 68 / 640 (10,6%) | 68 / 636 (10,7%) | 0,99 | [0,72;1,37] |
All cause death
Amputation
Relative risks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Endpoint | Events (%) | Relative Risk | 95% CI | Endpoint definition in the trial |
Ref | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Studied treat. | Control treat. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
All cause death | 115 / 640 (18,0%) | 80 / 636 (12,6%) | 1,43 | [1,10;1,86] | Death (any cause) | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amputation | 10 / 640 (1,6%) | 10 / 636 (1,6%) | 0,99 | [0,42;2,37] | Above ankle amputation for critical limb ischaemia | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The primary endpoint (if exists) appears in blod characters | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reference(s) used for data extraction:
|
Absolute risk reduction (for a follow-up of ) | ||||
Endpoint | Events rate | Absolute risk reduction (ARR) |
||
---|---|---|---|---|
Studied treat. | Control treat. | |||
All cause death | 17,97% | 12,58% | 5,4% | |
Amputation | 1,56% | 1,57% | -0,01% |
Meta-analysis of all similar trials:
antioxydants in cardiovascular prevention for all type of patients
antioxydants in cardiovascular prevention for diabetic patients
antioxydants in diabetes type 2 for all type of patients
antioxydants in peripheral vascular diseases for diabetic patients
antioxydants in peripheral vascular diseases for all type of patients
TrialResults-center ID | TRC8776 |
Trials register # | ISRCTN53295293 |
(c) 2004-2016 TrialResults-center - All Rights Reserved
Tweet this
|
Facebook
|
notify a friend
100Heart and vessels